Camrelizumab plus famitinib as first-line treatment in advanced NSCLC patients with PD-L1 TPS ≥1%: A report from a multicenter, open-label, phase II basket trial

被引：0
|
作者：
Ren, S. [1 ]
Wang, X. [2 ]
Han, B. [3 ]
Pan, Y. [4 ]
Zhao, J. [5 ]
Cheng, Y. [6 ,10 ]
Hu, S. [7 ]
Liu, T. [8 ]
Li, Y. [9 ]
Cheng, Y. [6 ,10 ]
Feng, J. [11 ]
Yi, S. [12 ]
Gu, S. [13 ]
Gao, S. [14 ]
Luo, Y. [15 ,16 ]
Liu, Y. [17 ]
Liu, C. [18 ]
Duan, H. [19 ]
Zhou, C. [1 ]
Fan, J. [20 ]
机构：
[1] Shanghai Pulm Hosp, Oncol Dept, Shanghai, Peoples R China
[2] Guangdong Pharmaceut Univ, Dept Oncol, Affiliated Hosp 1, Guangzhou, Peoples R China
[3] Shanghai Chest Hosp, Dept Resp, Shanghai, Peoples R China
[4] USTC, Oncol Chemotherapy Dept, Affiliated Hosp 1, Anhui Prov Hosp, Hefei, Peoples R China
[5] Beijing Canc Hosp, Dept Thorac Med Oncol, Beijing, Peoples R China
[6] Shandong Univ, Dept Chemotherapy, Qilu Hosp, Jinan, Peoples R China
[7] Hubei Canc Hosp, Dept Thorac Tumor, Wuhan, Peoples R China
[8] Fudan Univ, Dept Med Oncol, Med Oncol Dept, Zhongshan Hosp, Shanghai, Peoples R China
[9] Sichuan Univ, Resp & Crit Care Med, West China Hosp, West China Sch Med, Chengdu, Peoples R China
[10] Jilin Canc Hosp, Dept Med Oncol, Changchun, Peoples R China
[11] Nanjing Med Univ, Jiangsu Inst Canc Res, Jiangsu Canc Hosp, Dept Med Oncol,Affiliated Canc Hosp, Nanjing, Peoples R China
[12] Zhengzhou Cent Hosp, Dept Med Oncol, Zhengzhou, Peoples R China
[13] Hunan Canc Hosp, Dept Intervent Radiol, Changsha, Peoples R China
[14] Henan Univ Sci & Technol, Dept Med Oncol, Affiliated Hosp 1, Luoyang, Peoples R China
[15] Cent South Univ, Thorac Med Dept, Hunan Canc Hosp, Changsha, Peoples R China
[16] Cent South Univ, Affiliated Canc Hosp, Xiangya Sch Med, Changsha, Peoples R China
[17] Zhengzhou Univ, Henan Canc Hosp, Dept Gastroenterol, Affiliated Canc Hosp, Zhengzhou, Peoples R China
[18] China Med Univ, Dept Oncol, Shengjing Hosp, Shenyang, Peoples R China
[19] Jiangsu Hengrui Pharmaceut Co Ltd, Clin Res & Dev, Shanghai, Peoples R China
[20] Fudan Univ, Zhongshan Hosp, Dept Liver Surg & Transplantat, Shanghai, Peoples R China
来源：
JOURNAL OF THORACIC ONCOLOGY | 2023年 / 18卷 / 04期
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
43P
引用
收藏
页码：S66 / S67
页数：2
相关论文
共 50 条
  • [41] Study protocol: A single-arm, multicenter, phase II trial of camrelizumab plus apatinib for advanced nonsquamous NSCLC previously treated with first-line immunotherapy
    Xing, Puyuan
    Wang, Mengzhao
    Zhao, Jun
    Zhong, Wei
    Chi, Yujia
    Xu, Ziyi
    Li, Junling
    THORACIC CANCER, 2021, 12 (20) : 2825 - 2828
  • [42] Anlotinib combined with TQB2450 (PD-L1 blockade) as first-line treatment for advanced esophageal squamous cell carcinoma (ESCC): A single-arm, multicenter, open-label phase. clinical trial.
    Yang, Xiuli
    Meng, Xiangrui
    Hong, Yong-Gui
    Zhang, Zhiye
    Xia, Jin
    Wu, Tao
    Chen, Yunfang
    Shan, Zheng-Zheng
    Fan, Qingxia
    Wang, Feng
    JOURNAL OF CLINICAL ONCOLOGY, 2023, 41 : 377 - 377
  • [43] Cemiplimab, a Human PD-1 Monoclonal Antibody, Versus Chemotherapy in First-Line Treatment of Advanced NSCLC with PD-L1 ≥50%
    Sezer, A.
    Gogishvili, M.
    Bentsion, D.
    Kilickap, S.
    Lowczak, A.
    Gumus, M.
    Gladkov, O.
    Clingan, P.
    Sriuranpong, V.
    Rizvi, N.
    Lee, S.
    Li, S.
    Snodgrass, P.
    Navarro, M.
    Lowy, I.
    Rietschel, P.
    JOURNAL OF THORACIC ONCOLOGY, 2019, 14 (10) : S638 - S638
  • [44] Cost-effectiveness analysis of pembrolizumab plus chemotherapy with PD-L1 test for the first-line treatment of NSCLC
    Wan, Ning
    Zhang, Tian-tian
    Hua, Si-hua
    Lu, Zi-luo
    Ji, Bo
    Li, Li-xia
    Lu, Li-qing
    Huang, Wen-jie
    Jiang, Jie
    Li, Jian
    CANCER MEDICINE, 2020, 9 (05): : 1683 - 1693
  • [45] Lenvatinib Plus PD-1 Inhibitors as First-Line Treatment in Patients With Unresectable Biliary Tract Cancer: A Single-Arm, Open-Label, Phase II Study
    Zhang, Qiyi
    Liu, Xingyu
    Wei, Shumei
    Zhang, Lufei
    Tian, Yang
    Gao, Zhenzhen
    Jin, Ming
    Yan, Sheng
    FRONTIERS IN ONCOLOGY, 2021, 11
  • [46] Sunitinib Plus Paclitaxel Versus Bevacizumab Plus Paclitaxel for First-Line Treatment of Patients With Advanced Breast Cancer: A Phase III, Randomized, Open-Label Trial
    Robert, Nicholas J.
    Saleh, Mansoor N.
    Paul, Devchand
    Generali, Daniele
    Gressot, Laurent
    Copur, Mehmet S.
    Brufsky, Adam M.
    Minton, Susan E.
    Giguere, Jeffrey K.
    Smith, John W., II
    Richards, Paul D.
    Gernhardt, Diana
    Huang, Xin
    Liau, Katherine F.
    Kern, Kenneth A.
    Davis, John
    CLINICAL BREAST CANCER, 2011, 11 (02) : 82 - 92
  • [47] Multicenter randomized, open-label phase II trial of sequential erlotinib and gemcitabine compared with gemcitabine monotherapy as first-line therapy in elderly or ECOG PS two patients with advanced NSCLC
    Michael, Michael
    White, Shane C.
    Abdi, Ehtesham
    Nott, Louise
    Clingan, Phillip
    Zimet, Allan
    Button, Peter
    Gregory, Daniel
    Solomon, Benjamin
    Dobrovic, Alexander
    Do, Hongdo
    Clarke, Stephen
    ASIA-PACIFIC JOURNAL OF CLINICAL ONCOLOGY, 2015, 11 (01) : 4 - 14
  • [48] RESULTS FROM AN ONGOING OPEN-LABEL, MULTICENTER, PHASE 1 TRIAL OF CCX559, AN ORALLY ADMINISTERED SMALL MOLECULE PD-L1 INHIBITOR, IN PATIENTS WITH ADVANCED SOLID TUMORS
    Tapia-Rico, Gonzalo
    Lundy, Joanne
    Richardson, Gary
    Zhao, Niky
    Ebsworth, Karen
    Yue, Huibin
    Miao, Shichiang
    deGoma, Emil
    Jain, Rita
    Schall, Thomas
    Sullivan, Kathleen
    Zhang, Penglie
    de Souza, Paul
    deGoma, Emil
    JOURNAL FOR IMMUNOTHERAPY OF CANCER, 2022, 10 : A800 - A800
  • [49] A Matching-Adjusted Indirect Comparison of Pembrolizumab plus Chemotherapy vs. Nivolumab plus Ipilimumab as First-Line Therapies in Patients with PD-L1 TPS ≥1% Metastatic NSCLC
    Halmos, Balazs
    Burke, Thomas
    Kalyvas, Chrysostomos
    Insinga, Ralph
    Vandormael, Kristel
    Frederickson, Andrew
    Piperdi, Bilal
    CANCERS, 2020, 12 (12) : 1 - 15
  • [50] Cemiplimab monotherapy for first-line treatment of advanced non-small-cell lung cancer with PD-L1 of at least 50%: a multicentre, open-label, global, phase 3, randomised, controlled trial
    Sezer, Ahmet
    Kilickap, Saadettin
    Gumus, Mahmut
    Bondarenko, Igor
    Ozguroglu, Mustafa
    Gogishvili, Miranda
    Turk, Haci M.
    Cicin, Irfan
    Bentsion, Dmitry
    Gladkov, Oleg
    Clingan, Philip
    Sriuranpong, Virote
    Rizvi, Naiyer
    Gao, Bo
    Li, Siyu
    Lee, Sue
    McGuire, Kristina
    Chen, Chieh-, I
    Makharadze, Tamta
    Paydas, Semra
    Nechaeva, Marina
    Seebach, Frank
    Weinreich, David M.
    Yancopoulos, George D.
    Gullo, Giuseppe
    Lowy, Israel
    Rietschel, Petra
    LANCET, 2021, 397 (10274): : 592 - 604
12345